David Brent Shafer
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
BTIG Maintains Buy on TCMD, Lowers Price Target to $35. BTIG kept its rating on Tactile Systems Technology while reducing its price target to $35. The new target sits below the analysts' average target of $39 and is near the stock's recent 52‑week high of $37.77. The adjustment may reflect BTIG's view on the company's near‑term outlook.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Baxter International publishes inaugural Connected Hospital Report. Baxter International released its first Connected Hospital Report, highlighting its role in remote cardiac monitoring and digital health infrastructure. The company is also featured in recent discussions regarding potential warning signs in Wall Street favorites and overlooked investment angles. These developments provide context for the stock's current position within its 52-week range.
Transaction History
| VCYT | ▲ Buy | Grant | 5,272 | $0 | 6/11/2026 | View on chart |
| TCMD | ▲ Buy | Grant | 6,521 | $0 | 5/6/2026 | View on chart |
| BAX | ▲ Buy | Grant | 12,836 | $0 | 5/5/2026 | View on chart |
| BAX | ▼ Sell | Tax Withholding | 31,337 | $762K | 8/19/2025 | View on chart |
| VCYT | ▲ Buy | Grant | 9,321 | $0 | 6/18/2025 | View on chart |
| TCMD | ▲ Buy | Grant | 16,078 | $0 | 5/7/2025 | View on chart |
| BAX | ▲ Buy | Grant | 76,289 | $0 | 2/5/2025 | View on chart |
| VCYT | ▲ Buy | Grant | 16,507 | $0 | 9/3/2024 | View on chart |
| TCMD | ▲ Buy | Grant | 10,469 | $0 | 5/8/2024 | View on chart |
| BAX | ▲ Buy | Grant | 5,952 | $0 | 5/7/2024 | View on chart |
| TCMD | ▲ Buy | Grant | 7,737 | $0 | 5/8/2023 | View on chart |
| BAX | ▲ Buy | Grant | 4,573 | $0 | 5/2/2023 | View on chart |
| BAX | ▲ Buy | Grant | 2,481 | $0 | 5/10/2022 | View on chart |
| TCMD | ▲ Buy | Grant | 12,103 | $0 | 5/9/2022 | View on chart |
| TCMD | ▲ Buy | Grant | 2,435 | $0 | 2/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Veracyte (VCYT) Stock Seen as Undervalued After 107% Rise
Recent coverage notes that Veracyte’s shares have risen more than 100% while still appearing inexpensive relative to its earnings multiple. The company’s trailing P/E of about 30.6 and an analyst consensus target near $58 suggest the market may be pricing in further upside. The stock is currently trading near the lower end of its 52‑week range, close to a support level that has been tested multiple times.
Veracyte (VCYT) Stock Seen as Undervalued After 107% Rise. Recent coverage notes that Veracyte’s shares have risen more than 100% while still appearing inexpensive relative to its earnings multiple. The company’s trailing P/E of about 30.6 and an analyst consensus target near $58 suggest the market may be pricing in further upside. The stock is currently trading near the lower end of its 52‑week range, close to a support level that has been tested multiple times.